Shock Wave Lithotripsy Versus Visual Cystolitholapaxy in The Management of Patients Presenting With Calcular Acute Urinary Retention: A Randomized Controlled Trial.

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02594631

Enrollment

100

Registered

2015-11-03

Start date

2015-03-31

Completion date

2016-04-30

Last updated

2015-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Calculi

Keywords

Urethral stones, Acute Cacular urinary retention, Extracorporeal Shock Wave Lithotripsy (ESWL), Visual lithotripsy, bladder stone

Brief summary

The aim of the study is to compare the safety and efficacy of ESWL and visual cystolitholapaxy in management of calcular acute urine retention.

Detailed description

Patients who present with acute urinary retention due to stone in the urethra or urinary bladder will be randomly assigned to receive treatment either by extracorporeal shock wave lithotripsy or by endoscopic visual cystolitholapaxy where patients and stone characteristics will be recorded and the outcome including the intraoperative and postoperative complications and the stone free rate will be also evaluated

Interventions

PROCEDUREESWL

Patients in this arm will receive ESWL for treatment of acute calcular urinary retention

PROCEDUREEndoscopic treatment

Patients in this arm will receive endoscopic treatment of acute calcular urinary retention

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

1. Adult male patients presenting with acute urinary retention due to urethral or urinary bladder stones. 2. with a stone size not more than 2 centimeters in greatest diameter. 3. No more than 2 stones.

Exclusion criteria

1. Bladder cancer. 2. Bladder replacement of any type. 3. Infravesical obstruction, due to marked benign prostatic hyperplasia, prostate cancer, stricture urethra or external urethral meatal stenosis.

Design outcomes

Primary

Measure	Time frame	Description
Stone free rate	1 week	evaluation of stone free rate after the assigned intevention

Secondary

Measure	Time frame	Description
Adverse events after the assigned intervention	1 month	evaluation of adverse events after the assigned intervention

Countries

Egypt

Contacts

Primary ContactMohamed I Ali, Dr

dr.m.ali.board@gmail.com0020502202222

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026